Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.

Jaidee, Rattanaporn; Kukongviriyapan, Veerapol; Senggunprai, Laddawan; Prawan, Auemduan; Jusakul, Apinya; Laphanuwat, Phatthamon; Kongpetch, Sarinya

Jaidee, Rattanaporn; Kukongviriyapan, Veerapol; Senggunprai, Laddawan; Prawan, Auemduan; Jusakul, Apinya; Laphanuwat, Phatthamon; Kongpetch, Sarinya.

Afiliación

Jaidee R; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Kukongviriyapan V; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Senggunprai L; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Prawan A; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Jusakul A; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand; Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.
Laphanuwat P; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Kongpetch S; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: sarinyako@kku.ac.th.

Life Sci ; 296: 120427, 2022 May 01.

Article en En | MEDLINE | ID: mdl-35218764

Asunto(s)

Neoplasias de los Conductos Biliares/tratamiento farmacológico; Colangiocarcinoma/tratamiento farmacológico; Desoxicitidina/análogos & derivados; Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/metabolismo; Antimetabolitos Antineoplásicos/farmacología; Neoplasias de los Conductos Biliares/metabolismo; Neoplasias de los Conductos Biliares/patología; Puntos de Control del Ciclo Celular/efectos de los fármacos; Línea Celular Tumoral; Movimiento Celular/efectos de los fármacos; Movimiento Celular/genética; Proliferación Celular/efectos de los fármacos; Colangiocarcinoma/metabolismo; Colangiocarcinoma/patología; Desoxicitidina/farmacología; Resistencia a Antineoplásicos/efectos de los fármacos; Transición Epitelial-Mesenquimal/efectos de los fármacos; Transición Epitelial-Mesenquimal/fisiología; Humanos; Neovascularización Patológica/tratamiento farmacológico; Neovascularización Patológica/patología; Proteínas Proto-Oncogénicas c-akt/metabolismo; Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/antagonistas & inhibidores; Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/genética; Transducción de Señal/efectos de los fármacos; Serina-Treonina Quinasas TOR/metabolismo; Gemcitabina

Palabras clave

Cholangiocarcinoma; FGFR inhibitor; FGFR2; Infigratinib; mTOR

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma / Desoxicitidina / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos Idioma: En Revista: Life Sci Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google